{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:52:41Z","timestamp":1791492761861,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"DOI":"10.1007\/s00401-026-02991-x","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:51:59Z","timestamp":1771437119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neuropathologic basis of quantitative susceptibility mapping in the substantia nigra: contributions of tau, pigmented neurons, and iron"],"prefix":"10.1007","volume":"151","author":[{"given":"Daisuke","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravya","family":"Kondrakunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Przybelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Fought","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aivi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross R.","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Senjem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toji","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah K.","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Savica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik K. St.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neill R.","family":"Graff-Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanis J.","family":"Ferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley F.","family":"Boeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejal","family":"Kantarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2991_CR1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC","edition":"4"},{"key":"2991_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.media.2007.06.004","volume":"12","author":"BB Avants","year":"2008","unstructured":"Avants BB, Epstein CL, Grossman M, Gee JC (2008) Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12:26\u201341","journal-title":"Med Image Anal"},{"key":"2991_CR3","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/brain\/awx137","volume":"140","author":"S Ayton","year":"2017","unstructured":"Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY et al (2017) Cerebral quantitative susceptibility mapping predicts amyloid-\u03b2-related cognitive decline. Brain 140:2112\u20132119","journal-title":"Brain"},{"key":"2991_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116443","volume":"406","author":"M Azuma","year":"2019","unstructured":"Azuma M, Hirai T, Nakaura T, Kitajima M, Yamashita S, Hashimoto M et al (2019) Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson\u2019s disease. J Neurol Sci 406:116443","journal-title":"J Neurol Sci"},{"key":"2991_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3174\/ajnr.A4645","volume":"37","author":"M Azuma","year":"2016","unstructured":"Azuma M, Hirai T, Yamada K, Yamashita S, Ando Y, Tateishi M et al (2016) Lateral asymmetry and spatial difference of iron deposition in the substantia nigra of patients with Parkinson disease measured with quantitative susceptibility mapping. AJNR Am J Neuroradiol 37:782\u2013788","journal-title":"AJNR Am J Neuroradiol"},{"key":"2991_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1148\/radiol.2021203341","volume":"300","author":"YJ Bae","year":"2021","unstructured":"Bae YJ, Kim J-M, Sohn C-H, Choi J-H, Choi BS, Song YS et al (2021) Imaging the substantia nigra in Parkinson disease and other parkinsonian syndromes. Radiology 300:260\u2013278","journal-title":"Radiology"},{"key":"2991_CR7","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878","journal-title":"Sci Rep"},{"key":"2991_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mds.27730","volume":"34","author":"N Bergsland","year":"2019","unstructured":"Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T Jr (2019) Ventral posterior substantia nigra iron increases over 3 years in Parkinson\u2019s disease. Mov Disord 34:1006\u20131013","journal-title":"Mov Disord"},{"key":"2991_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf325","author":"R Bhome","year":"2025","unstructured":"Bhome R, Thomas GEC, Hannaway N, Dobreva I, Zarkali A, Shmueli K et al (2025) Quantitative susceptibility mapping reveals differences between subtypes of Lewy body dementia. Brain. https:\/\/doi.org\/10.1093\/brain\/awaf325","journal-title":"Brain"},{"key":"2991_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259","journal-title":"Acta Neuropathol"},{"key":"2991_CR11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/jon.12878","volume":"31","author":"Q Chen","year":"2021","unstructured":"Chen Q, Boeve BF, Forghanian-Arani A, Senjem ML, Jack CR Jr, Przybelski SA et al (2021) MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. J Neuroimaging 31:1020\u20131027","journal-title":"J Neuroimaging"},{"key":"2991_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117433","volume":"224","author":"PM Cogswell","year":"2021","unstructured":"Cogswell PM, Wiste HJ, Senjem ML, Gunter JL, Weigand SD, Schwarz CG et al (2021) Associations of quantitative susceptibility mapping with Alzheimer\u2019s disease clinical and imaging markers. Neuroimage 224:117433","journal-title":"Neuroimage"},{"key":"2991_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103478","volume":"79","author":"MJ da Costa Caiado","year":"2025","unstructured":"da Costa Caiado MJ, Dolga AM, den Dunnen WFA (2025) Iron(ing) out parkinsonisms: the interplay of proteinopathy and ferroptosis in Parkinson\u2019s disease and tau-related parkinsonisms. Redox Biol 79:103478","journal-title":"Redox Biol"},{"issue":"(Pt 8)","key":"2991_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/brain\/122.8.1421","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 122((Pt 8)):1421\u20131436","journal-title":"Brain"},{"key":"2991_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30265","author":"P Diaz-Galvan","year":"2025","unstructured":"Diaz-Galvan P, Przybelski SA, Lesnick TG, Murray ME, Nguyen A, Reichard RR et al (2025) Substantia nigra iron deposition in Lewy body disease: a magnetic resonance imaging and neuropathology study. Mov Disord. https:\/\/doi.org\/10.1002\/mds.30265","journal-title":"Mov Disord"},{"key":"2991_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","volume":"23","author":"DW Dickson","year":"2010","unstructured":"Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA (2010) Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 23:394\u2013400","journal-title":"Curr Opin Neurol"},{"key":"2991_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","volume":"61","author":"DW Dickson","year":"2002","unstructured":"Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K et al (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935\u2013946","journal-title":"J Neuropathol Exp Neurol"},{"key":"2991_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neuroimage.2017.05.015","volume":"170","author":"S Ewert","year":"2018","unstructured":"Ewert S, Plettig P, Li N, Chakravarty MM, Collins DL, Herrington TM et al (2018) Toward defining deep brain stimulation targets in MNI space: a subcortical atlas based on multimodal MRI, histology and structural connectivity. Neuroimage 170:271\u2013282","journal-title":"Neuroimage"},{"key":"2991_CR19","unstructured":"Fahn S (1987) Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson\u2019s disease. Macmillan health care information, vol 2, pp 153\u2013163"},{"issue":"Pt 5","key":"2991_CR20","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ (1991) Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283\u20132301","journal-title":"Brain"},{"key":"2991_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109394","volume":"133","author":"MP Fedeli","year":"2020","unstructured":"Fedeli MP, Contarino VE, Siggillino S, Samoylova N, Calloni S, Melazzini L et al (2020) Iron deposition in Parkinsonisms: a quantitative susceptibility mapping study in the deep grey matter. Eur J Radiol 133:109394","journal-title":"Eur J Radiol"},{"key":"2991_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"2991_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mri.2014.09.004","volume":"33","author":"EM Haacke","year":"2015","unstructured":"Haacke EM, Liu S, Buch S, Zheng W, Wu D, Ye Y (2015) Quantitative susceptibility mapping: current status and future directions. Magn Reson Imaging 33:1\u201325","journal-title":"Magn Reson Imaging"},{"key":"2991_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0404.1989.tb01778.x","volume":"126","author":"EC Hirsch","year":"1989","unstructured":"Hirsch EC, Graybiel AM, Agid Y (1989) Selective vulnerability of pigmented dopaminergic neurons in Parkinson\u2019s disease. Acta Neurol Scand Suppl 126:19\u201322","journal-title":"Acta Neurol Scand Suppl"},{"key":"2991_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566\u2013572","journal-title":"Br J Psychiatry"},{"key":"2991_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8:1\u201313","journal-title":"Alzheimers Dement"},{"key":"2991_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00234-017-1870-7","volume":"59","author":"K Ito","year":"2017","unstructured":"Ito K, Ohtsuka C, Yoshioka K, Kameda H, Yokosawa S, Sato R et al (2017) Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping. Neuroradiology 59:759\u2013769","journal-title":"Neuroradiology"},{"key":"2991_CR28","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.neurobiolaging.2011.09.024","volume":"33","author":"K Kantarci","year":"2012","unstructured":"Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA et al (2012) Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 33:2091\u20132105","journal-title":"Neurobiol Aging"},{"key":"2991_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162460","volume":"11","author":"C Langkammer","year":"2016","unstructured":"Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S et al (2016) Quantitative susceptibility mapping in Parkinson\u2019s disease. PLoS ONE 11:e0162460","journal-title":"PLoS ONE"},{"key":"2991_CR30","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.neuroimage.2012.05.049","volume":"62","author":"C Langkammer","year":"2012","unstructured":"Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E et al (2012) Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage 62:1593\u20131599","journal-title":"Neuroimage"},{"key":"2991_CR31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/mds.27381","volume":"33","author":"MM Lewis","year":"2018","unstructured":"Lewis MM, Du G, Baccon J, Snyder AM, Murie B, Cooper F et al (2018) Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes. Mov Disord 33:1432\u20131439","journal-title":"Mov Disord"},{"key":"2991_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/nbm.3056","volume":"27","author":"W Li","year":"2014","unstructured":"Li W, Avram AV, Wu B, Xiao X, Liu C (2014) Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping: HARPERELLA PHASE PROCESSING. NMR Biomed 27:219\u2013227","journal-title":"NMR Biomed"},{"key":"2991_CR33","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.neuroimage.2010.11.088","volume":"55","author":"W Li","year":"2011","unstructured":"Li W, Wu B, Liu C (2011) Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 55:1645\u20131656","journal-title":"Neuroimage"},{"key":"2991_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies. Neurology 89:88\u2013100","journal-title":"Neurology"},{"key":"2991_CR35","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1001\/archneur.58.11.1803","volume":"58","author":"GM McKhann","year":"2001","unstructured":"McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ et al (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick\u2019s Disease. Arch Neurol 58:1803\u20131809","journal-title":"Arch Neurol"},{"key":"2991_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269","journal-title":"Alzheimers Dement"},{"key":"2991_CR37","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/alz.12321","volume":"17","author":"CM Moloney","year":"2021","unstructured":"Moloney CM, Lowe VJ, Murray ME (2021) Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement 17:1554\u20131574","journal-title":"Alzheimers Dement"},{"key":"2991_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol 123:1\u201311","journal-title":"Acta Neuropathol"},{"key":"2991_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW (2011) Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785\u2013796","journal-title":"Lancet Neurol"},{"key":"2991_CR40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.neuroimage.2017.08.003","volume":"159","author":"J O\u2019Callaghan","year":"2017","unstructured":"O\u2019Callaghan J, Holmes H, Powell N, Wells JA, Ismail O, Harrison IF et al (2017) Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer\u2019s disease. Neuroimage 159:334\u2013345","journal-title":"Neuroimage"},{"key":"2991_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14628","volume":"21","author":"D Ono","year":"2025","unstructured":"Ono D, Sekiya H, Maier AR, Murray ME, Koga S, Dickson DW (2025) Parkinsonism in Alzheimer\u2019s disease without Lewy bodies in association with nigral neuron loss: a data-driven clinicopathologic study. Alzheimers Dement 21:e14628","journal-title":"Alzheimers Dement"},{"key":"2991_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183\u2013194","journal-title":"J Intern Med"},{"key":"2991_CR43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1212\/WNL.0b013e3181f11d85","volume":"75","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS et al (2010) Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 75:889\u2013897","journal-title":"Neurology"},{"key":"2991_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF et al (2008) The Mayo Clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30:58\u201369","journal-title":"Neuroepidemiology"},{"key":"2991_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-022-02479-4","volume":"144","author":"SF Roemer","year":"2022","unstructured":"Roemer SF, Grinberg LT, Crary JF, Seeley WW, McKee AC, Kovacs GG et al (2022) Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. Acta Neuropathol 144:603\u2013614","journal-title":"Acta Neuropathol"},{"key":"2991_CR46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.20226","volume":"56","author":"GW Ross","year":"2004","unstructured":"Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D et al (2004) Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 56:532\u2013539","journal-title":"Ann Neurol"},{"key":"2991_CR47","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/mds.29613","volume":"38","author":"R Satoh","year":"2023","unstructured":"Satoh R, Weigand SD, Pham NTT, Ali F, Arani A, Senjem ML et al (2023) Magnetic susceptibility in progressive supranuclear palsy variants, Parkinson\u2019s disease, and corticobasal syndrome. Mov Disord 38:2282\u20132290","journal-title":"Mov Disord"},{"key":"2991_CR48","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1364\/OL.28.001194","volume":"28","author":"MA Schofield","year":"2003","unstructured":"Schofield MA, Zhu Y (2003) Fast phase unwrapping algorithm for interferometric applications. Opt Lett 28:1194\u20131196","journal-title":"Opt Lett"},{"key":"2991_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K et al (2022) Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease. Acta Neuropathol Commun 10:133","journal-title":"Acta Neuropathol Commun"},{"key":"2991_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.08.029","volume":"44","author":"H Sj\u00f6str\u00f6m","year":"2017","unstructured":"Sj\u00f6str\u00f6m H, Granberg T, Westman E, Svenningsson P (2017) Quantitative susceptibility mapping differentiates between parkinsonian disorders. Parkinsonism Relat Disord 44:51\u201357","journal-title":"Parkinsonism Relat Disord"},{"key":"2991_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42565-4","volume":"9","author":"H Sj\u00f6str\u00f6m","year":"2019","unstructured":"Sj\u00f6str\u00f6m H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D et al (2019) Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. Sci Rep 9:6079","journal-title":"Sci Rep"},{"key":"2991_CR52","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/brain\/awaa089","volume":"143","author":"N Spotorno","year":"2020","unstructured":"Spotorno N, Acosta-Cabronero J, Stomrud E, Lampinen B, Strandberg OT, van Westen D et al (2020) Relationship between cortical iron and tau aggregation in Alzheimer\u2019s disease. Brain 143:1341\u20131349","journal-title":"Brain"},{"issue":"Pt 1","key":"2991_CR53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuroimage.2014.02.026","volume":"93","author":"C St\u00fcber","year":"2014","unstructured":"St\u00fcber C, Morawski M, Sch\u00e4fer A, Labadie C, W\u00e4hnert M, Leuze C et al (2014) Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. Neuroimage 93(Pt 1):95\u2013106","journal-title":"Neuroimage"},{"key":"2991_CR54","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, R\u00fcb U, Orantes M, Braak H (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791\u20131800","journal-title":"Neurology"},{"key":"2991_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF00296789","volume":"83","author":"T Uchihara","year":"1992","unstructured":"Uchihara T, Kondo H, Kosaka K, Tsukagoshi H (1992) Selective loss of nigral neurons in Alzheimer\u2019s disease: a morphometric study. Acta Neuropathol 83:271\u2013276","journal-title":"Acta Neuropathol"},{"key":"2991_CR56","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/01.jnen.0000225908.90052.07","volume":"65","author":"H Uchikado","year":"2006","unstructured":"Uchikado H, Lin W-L, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65:685\u2013697","journal-title":"J Neuropathol Exp Neurol"},{"key":"2991_CR57","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mds.29311","volume":"38","author":"EW Wang","year":"2023","unstructured":"Wang EW, Brown GL, Lewis MM, Jellen LC, Pu C, Johnson ML et al (2023) Susceptibility magnetic resonance imaging correlates with glial density and Tau in the substantia nigra pars compacta. Mov Disord 38:464\u2013473","journal-title":"Mov Disord"},{"key":"2991_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mrm.25358","volume":"73","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu T (2015) Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker: QSM. Magn Reson Med 73:82\u2013101","journal-title":"Magn Reson Med"},{"key":"2991_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-016-0064-2","volume":"5","author":"Z Wang","year":"2016","unstructured":"Wang Z, Luo X-G, Gao C (2016) Utility of susceptibility-weighted imaging in Parkinson\u2019s disease and atypical Parkinsonian disorders. Transl Neurodegener 5:17","journal-title":"Transl Neurodegener"},{"key":"2991_CR60","first-page":"414","volume":"54","author":"L Zecca","year":"2001","unstructured":"Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D (2001) Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 54:414\u2013418","journal-title":"Mol Pathol"},{"key":"2991_CR61","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3233\/JPD-223499","volume":"12","author":"D Zhang","year":"2022","unstructured":"Zhang D, Yao J, Sun J, Tong Q, Zhu S, Wang J et al (2022) Quantitative susceptibility mapping and free water imaging of substantia nigra in Parkinson\u2019s disease. J Parkinsons Dis 12:2469\u20132478","journal-title":"J Parkinsons Dis"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-026-02991-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-026-02991-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-026-02991-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:02:26Z","timestamp":1771437746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-026-02991-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s00401-026-02991-x","relation":{},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.K., E.M., S.A.P., A.F., A.N., R.R.R., J.L.G., T.M., L.K.F., J.A.F., R.S., D.T.J., H.B., N.R.G-R., G.S.D., and W.K.K. report no disclosures relevant to the manuscript. D.O. receives research support from the Japan Science and Technology Agency and the Japan Society for the Promotion of Science. D.W.D receives research support from NIH. C.G.S. receives research support from the NIH. M.L.S. owns or has owned stock in medical-related companies, unrelated to the current work, within the past 36\u00a0months: Align Technology, Inc., Inovio Pharmaceuticals, Inc., Mesa Laboratories, Inc., Johnson and Johnson, LHC Group, Inc., Natus Medical Inc., and Varex Imaging Corporation. C.R.J. has consulted for Lily and serves on an independent data monitoring board for Roche and as a speaker for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer\u2019s Disease Research Professorship of the Mayo Clinic. T.M. receives research support from National Institute of Health and Zander Family Foundation. V.K.R. receives research funding from the NIH and the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program and has provided educational content for Medscape, Expert Perspectives in Alzheimer\u2019s Disease, Clinical Care Options, and Roche\/ADLM; has received speaker and conference session honoraria from the American Academy of Neurology Institute; is PI for a clinical trial supported by the Alzheimer\u2019s Association; is site Co-PI for the Alzheimer\u2019s Clinical Trials Consortium; and is a site clinician for clinical trials supported by Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc., unrelated to this work. E.K.St.L. has no disclosures related to this work. He has served as a Co-Investigator on K.K. research grant (DLB U01) and as a NAPS co-investigator. D.S.K. serves on a Data Safety Monitoring Board for the DIAN study, has served on a Data Safety Monitoring Board for a tau therapeutic for Biogen but received no personal compensation, is a site investigator in Biogen aducanumab trials, is an investigator in clinical trials sponsored by Lilly Pharmaceuticals and the University of Southern California, serves as a consultant for Samus Therapeutics, Roche, Magellan Health and Alzeca Biosciences but receives no personal compensation, and receives research support from the NIH. T.J.F. serves as a consultant for Acadia pharmaceuticals and receives funding from NIH and the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program. V.J.L. serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). R.C.P. serves as a consultant for Roche, Inc., Merck, Inc., Biogen, Inc., Eisai, Inc., Genentech, Inc., and Nestle, Inc., served on a DSMB for Genentech, receives royalties from Oxford University Press and UpToDate, and receives NIH funding. B.F.B. has served as an investigator for clinical trials sponsored by Alector, Cognition Therapeutics, EIP Pharma\/Cervomed, and Transposon. He serves on the Scientific Advisory Board of the Tau Consortium, funded by the Rainwater Charitable Foundation. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Ted Turner and Family Foundation. K.K. consults for Biogen, Eisai, and BioArctic with no personal compensation, received research support from Avid Radiopharmaceuticals and Eli Lilly, and receives funding from NIH and Alzheimer\u2019s Drug Discovery Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}